Table 12.

Summary of Findings for PICO Question 9^a

Anti–IL-5 monoclonal antibodies compared to placebo for EoE
Outcomes and follow-up	No. of participants (studies)92–94	Certainty of the evidence (GRADE)	Relative effect, RR (95% CI)	Anticipated absolute effects
				Risk with placebo	Risk difference with anti–IL-5 monoclonal antibodies
Not achieving histologic remission (<15 eos/hpf) (remission, partial) assessed with: <15/hpf, follow-up: range 9 wk to 16 wk	286 (3 RCTs)b,c,d,e	⊕⊕◯◯ LOWf,g	0.92 (0.84 to 1.00)	902 per 1000	72 fewer per 1000 (144 fewer to 0 fewer)

^aThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

^bMepolizumab in adults (escalating mepolizumab doses) (Straumann et al⁹²).

^cMepolizumab in children, used very low dose mepolizumab as placebo or “comparator” group as suggested by authors in the Methods section; grouped other 2 doses of mepolizumab together (no obvious dose response); missing description of blinding and allocation concealment (Assa’ad et al⁹³).

^dReslizumab in children; grouped 3 doses of reslizumab together in intervention group (no obvious dose response) (Spergel et al⁹⁴).

^eParticipant selection for these studies are different than for other interventions—have failed many other interventions before enrolling in this study.

^fCI crosses 1.

^gCI touches 1 (upper boundary of CI is 1.0—no effect—which could lead to a different recommendation and therefore represents imprecision.